Application prospects of phased-array computed tomography in the diagnosis and treatment of digestive system diseases: A cross-sectional survey

Table 1 Basic information of respondents

Basic information	Content	Number	Percentage
Professional title	Resident	27	24.11
	Attending	47	41.96
	Associate chief	26	23.21
	Chief	12	10.71
Medical institution grade	Grade III class A	64	57.14
	Grade III class B	33	29.46
	Grade II class A	8	7.14
	Other	7	6.25
Department	Gastroenterology	74	66.07
	Gastrointestinal surgery	38	33.93
Primary subspecialty practice areas (multiple-choice)	Liver	41	36.61
	Biliary tract	29	25.89
	Pancreatic	31	27.68
	Gastrointestinal	82	73.21
	Interventional endoscopy	32	28.57
Experience	< 5 years	30	26.79
	5-10 years	37	33.04
	11-20 years	31	27.68
	> 20 years	14	12.50
Frequency of exposure to digestive system computed tomography	Almost daily	64	57.14
	3-4 times weekly	28	25.00
	1-2 times weekly	18	16.07
	Rarely	2	1.79

Table 2 Potential scores for phased-array computed tomography applications in digestive system diseases

Category	Application scenarios	Mean	SD
Liver	Early detection and differentiation of micro-liver cancer (< 1 cm) in the context of cirrhosis	4.33	0.71
	Early identification of liver metastases	4.32	0.68
	Precise differentiation of benign lesions such as focal nodular hyperplasia and hemangiomas	4.19	0.74
	Non-invasive quantitative assessment of liver fibrosis and cirrhosis	3.98	0.88
Pancreatic	Detection and staging of early pancreatic cancer	4.30	0.73
	Accurate assessment of the risk of malignant transformation in pancreatic cysts	4.23	0.72
	Differential diagnosis between chronic pancreatitis and pancreatic cancer	4.21	0.71
	Detailed evaluation of necrosis extent and vascular complications in acute pancreatitis	4.20	0.73
Gastrointestinal	Localization and risk stratification of submucosal tumors in the gastrointestinal tract	4.24	0.69
	Assessment of infiltration depth for early gastrointestinal cancers	4.17	0.77
	Evaluation of activity, extent, and complications (e.g., fistulas) in inflammatory bowel disease	4.16	0.77
Function and dynamic imaging	Quantitative analysis of organ blood perfusion	4.09	0.72
	Dynamic assessment of gastrointestinal motility	3.91	0.82
Interventional and surgical planning	Localization of ablation scope and efficacy assessment for liver and pancreatic tumors	4.42	0.69
	Pre-procedural vascular access planning and post-procedural assessment	4.07	0.74
	Precise preoperative assessment of liver vasculature and volume	4.04	0.74

Table 3 Results of subgroup analyses showing statistically significant differences

Dimension	Scenarios	Subgroup-1 (n)	M1 ± SD	Subgroup-2 (n)	M2 ± SD	Mean difference (95%CI)	t (degrees of freedom = 110)	P value	Cohen’s d value
Hospital grade	Detection and staging of early pancreatic cancer	Grade III class A (n = 64)	4.38 ± 0.71	Non-grade III class A (n = 48)	4.15 ± 0.73	0.23 (0.02-0.44)	2.18	0.032	0.32
	Dynamic assessment of gastrointestinal motility	Grade III class A (n = 64)	3.73 ± 0.90	Non-grade III class A (n = 48)	4.17 ± 0.76	0.44 (0.15-0.73)	3.04	0.003	0.52
Sub-specialty	Non-invasive quantitative assessment	Liver disease (n = 41)	4.12 ± 0.81	Non-liver disease (n = 71)	3.89 ± 0.91	0.23 (0.01-0.45)	2.07	0.041	0.27
	Assessment of necrotic extent in acute pancreatitis	Pancreatic disease (n = 31)	4.55 ± 0.57	Non-pancreatic disease (n = 81)	4.19 ± 0.81	0.36 (0.08-0.64)	2.50	0.014	0.48
	Pre-procedural planning and postoperative evaluation	Liver disease (n = 41)	4.32 ± 0.80	Non-liver disease (n = 71)	4.05 ± 0.80	0.27 (-0.04 to 0.58)	1.72	0.046	0.34
Professional title	Early gastrointestinal cancer invasion depth	Seniority (n = 38)	4.32 ± 0.68	Junior (n = 74)	4.05 ± 0.83	0.27 (0.03-0.51)	2.23	0.028	0.35
	Tumor ablation and evaluating treatment efficacy	Seniority (n = 38)	4.58 ± 0.55	Junior (n = 74)	4.30 ± 0.79	0.28 (0.02-0.54)	2.15	0.034	0.39

M1: Mean score for subgroup-1; M2: Mean score for subgroup-2.